4.5 Article

Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study

Journal

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
Volume 30, Issue 7, Pages 1349-1358

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-20-1848

Keywords

-

Funding

  1. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services [R01 CA176272]
  2. NIH/NCI Cancer Center Support grant [P30 CA015704]
  3. ORIP grant [S10OD028685]
  4. U.S. National Cancer Institute
  5. National Cancer Institute (NCI), National Institutes of Health (NIH) [U01 CA167551]
  6. NIH [U01 CA122839, R01 CA143247, U19 CA148107, R01 CA81488, HHSN268201200008I]
  7. Ontario Research Fund [GL201-043]
  8. Canadian Institutes of Health Research through a Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society [112746]
  9. Ontario Ministry of Research and Innovation
  10. NCI [R01 CA076366]
  11. German Research Council [BR 1704/6-1, BR 1704/6-3, BR1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, BR 1704/17-1]
  12. German Federal Ministry of Education and Research [01KH0404, 01ER0814, 01ER0815, 01ER1505A, 01ER1505B]
  13. Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT), Germany
  14. German Cancer Research Center
  15. National Institutes of Health [R01 CA48998, P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, R35 CA197735]
  16. NCI, EDRN Grant [U01 CA 84968-06]
  17. VicHealth
  18. National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health andHumanServices [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]

Ask authors/readers for more resources

This study utilized a Mendelian randomization approach to assess the association between CRP concentrations and colorectal cancer-specific survival, and found no causal effect of circulating CRP concentrations on colorectal cancer-specific survival. Further research on genetically determined levels of other inflammatory biomarkers is needed for colorectal cancer survival outcomes.
Background: A positive association between circulating C-reactive protein (CRP) and colorectal cancer survival was reported in observational studies, which are susceptible to unmeasured confounding and reverse causality. We used a Mendelian randomization approach to evaluate the association between genetically predicted CRP concentrations and colorectal cancer-specific survival. Methods: We used individual-level data for 16,918 eligible colorectal cancer cases of European ancestry from 15 studies within the International Survival Analysis of Colorectal Cancer Consortium. We calculated a genetic-risk score based on 52 CRP-associated genetic variants identified from genome-wide association studies. Because of the non-collapsibility of hazard ratios from Cox proportional hazards models, we used the additive hazards model to calculate hazard differences (HD) and 95% confidence intervals (CI) for the association between genetically predicted CRP concentrations and colorectal cancer-specific survival, overall and by stage at diagnosis and tumor location. Analyses were adjusted for age at diagnosis, sex, body mass index, genotyping platform, study, and principal components. Results: Of the 5,395 (32%) deaths accrued over up to 10 years of follow-up, 3,808 (23%) were due to colorectal cancer. Genetically predicted CRP concentration was not associated with colorectal cancer-specific survival (HD, -1.15; 95% CI, -2.76 to 0.47 per 100,000 person-years; P = 0.16). Similarly, no associations were observed in subgroup analyses by stage at diagnosis or tumor location. Conclusions: Despite adequate power to detect moderate associations, our results did not support a causal effect of circulating CRP concentrations on colorectal cancer-specific survival. Impact: Future research evaluating genetically determined levels of other circulating inflammatory biomarkers (i.e., IL6) with colorectal cancer survival outcomes is needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available